Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q15067

UPID:
ACOX1_HUMAN

ALTERNATIVE NAMES:
Palmitoyl-CoA oxidase; Peroxisomal fatty acyl-CoA oxidase; Straight-chain acyl-CoA oxidase

ALTERNATIVE UPACC:
Q15067; A8K6X8; A8KAA0; B4DK61; F5GYQ8; Q12863; Q15068; Q15101; Q16131; Q7Z3W5; Q9UD31

BACKGROUND:
Peroxisomal acyl-coenzyme A oxidase 1, identified by its alternative names such as Peroxisomal fatty acyl-CoA oxidase, is integral to the initial step of peroxisomal beta-oxidation. It exhibits highest activity against medium-chain fatty acyl-CoAs and is essential for the metabolism of straight-chain saturated and unsaturated very-long-chain fatty acids.

THERAPEUTIC SIGNIFICANCE:
Mutations affecting Peroxisomal acyl-coenzyme A oxidase 1 are implicated in the pathogenesis of Adrenoleukodystrophy, pseudoneonatal, and Mitchell syndrome. These conditions underscore the enzyme's therapeutic significance, as understanding its function and the impact of its dysregulation may lead to innovative treatments for these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.